Document Detail


Increase in pulmonary arterial diameter under prostaglandin E1 therapy in infants with cyanotic congenital heart disease.
MedLine Citation:
PMID:  9703565     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the change in pulmonary arterial diameter under prostaglandin E1 (PGE1) therapy in infants with ductus-dependent cyanotic heart disease (pulmonary atresia). Ten infants undergoing administration of PGE1 for more than 2 weeks were selected for this study. A classic Blalock-Taussig (BT) shunt was performed in seven patients and a modified BT shunt in three. The shunt was successful in all patients. The internal diameters of the right and left pulmonary arteries were measured before and after the start of PGE1 therapy using two-dimensional echocardiography. The pulmonary arterial index (PA index) was calculated to correct the diameters for body surface area. Both pulmonary arteries enlarged during the first week of PGE1 therapy in all 10 patients. Further increases in the two diameters were observed even after the first week of treatment in nine patients. Both the mean diameters at 2 weeks after the start of PGE1 were about 50% larger than the initial diameters (right; increased from 3.1 to 4.7 mm; left; increased from 3.0 to 4. 4 mm). Of the eight patients given PGE1 for more than 3 weeks, four showed no changes in pulmonary arterial diameters after the first 2 weeks and the remaining four showed a slight increase. PA indexes also showed a rapid increase during the first 2 weeks and no significant change thereafter. We suggest that, in infants with pulmonary atresia and small pulmonary arteries, the optimal pulmonary artery size for BT shunt insertion is achieved after 2 weeks of PGE1 infusion, with no further significant increase in size being observed after this time.
Authors:
T Ito; K Harada; M Tamura; G Takada
Related Documents :
6189635 - Hemodynamic assessment after palliative surgery for hypoplastic left heart syndrome.
16137505 - Echocardiographic automated cardiac output measurement of pulmonary output and quantifi...
8915715 - Quantification of pulmonary and systemic blood flow by magnetic resonance velocity mapp...
9237435 - Optimized transcranial doppler technique for the diagnosis of cardiac right-to-left shu...
15488095 - Aneurysm of sinus of valsalva dissecting into interventricular septum: a late complicat...
15658105 - Microsurgical anatomy of cerebral revascularization. part ii: posterior circulation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatric cardiology     Volume:  19     ISSN:  0172-0643     ISO Abbreviation:  Pediatr Cardiol     Publication Date:    1998 Sep-Oct
Date Detail:
Created Date:  1998-09-17     Completed Date:  1998-09-17     Revised Date:  2008-02-20    
Medline Journal Info:
Nlm Unique ID:  8003849     Medline TA:  Pediatr Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  404-7     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alprostadil / administration & dosage,  pharmacology*,  therapeutic use
Humans
Infant
Infant, Newborn
Infusions, Intra-Arterial
Muscle, Smooth, Vascular / drug effects*
Pulmonary Artery* / drug effects,  physiology
Pulmonary Atresia / drug therapy,  pathology*
Vasodilation / drug effects*
Vasodilator Agents / administration & dosage,  pharmacology*,  therapeutic use
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Experimental evidence of cerebral injury from profound hypothermia during cardiopulmonary bypass.
Next Document:  Responses of plasma norepinephrine and heart rate during exercise in patients after Fontan operation...